Ribonova

Executive Summary

Ribonova is a privately-held biopharmaceutical company dedicated to developing novel precision therapies for serious rare diseases, with a primary focus on mitochondrial disorders. Founded in 2018 and based near Philadelphia at the Lankenau Institute for Medical Research, the company leverages a proprietary platform targeting transfer RNA to create small molecule therapeutics. Its lead asset is a Phase 2-ready small molecule for genetically-confirmed mitochondrial disease, positioning the company for potential clinical milestones. Ribonova's approach addresses a significant unmet need in mitochondrial medicine, where few effective treatments exist. The company remains in early clinical development with no disclosed funding rounds or valuation, but its unique tRNA-targeting platform and Phase 2-ready asset represent a compelling opportunity in the rare disease space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 clinical trial for lead mitochondrial disease candidate60% success
• Q4 2026Presentation of preclinical data for novel tRNA-targeting platform at major medical conference70% success